Calculate your potential ROI with ACT

Tested in over 300 breast health clinics across the US, ACT has proven results across the board(1,2). Input your Total Annual Screenings to estimate the ROI ACT can have at your clinic.

Increase breast cancer screening compliance rates

Improve radiologists’ accuracy, productivity, and workflow

Optimize clinic operations to ensure patients receive timely and compassionate care

Total Annual Screenings

Calculate

Estimated ROI

0
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
0

This calculation is based on a global average screening reimbursement of $205 and is for estimation purposes only. Actual results will vary.

Footnotes

1. Compared to a previous average of about 1% or less growth per year.
2. Average growth rate across all clinics using ACT.

Products

ACT
ACT ROI
WRDensity
WRRisk
Request a Demo

Company

AboutOur TeamCareersContact

Privacy Policy

End User Agreement

Copyright © , Whiterabbit.ai

Artificial intelligence driven breast density software. 


WRDensity assists radiologists in interpreting breast density to create uniformity of density assessments at a practice level. The goal, aid in early detection¹ while giving patients peace of mind by improving consistency, confidence, and quality of care. 


What if we could ensure that every eligible woman gets her routine screening mammogram?

Find out how ACT can help do just that.

Play Video
How It Works

WRDensity provides an ACR BI-RADS 5th Edition breast density category to aid interpreting physicians in the assessment of breast tissue composition.

WRDensity was trained using deep learning based on over 600,000 images from Mallinckrodt Institute of Radiology, one of the world’s leading radiology research institutes.


Whiterabbit has been a fantastic partner in helping us modernize our breast cancer risk assessment program.  From the start, they really listened to us, understood what we needed and provided a sleek, agile program to give answers to our patients.  Whiterabbit has been a joy to work with, and are unfailingly nimble, insightful and quick – we greatly appreciate their depth of skill, from programming to design to breast cancer statistics.  With WRDensity, we are better able to manage our most at-risk patients.

‍

Dr. Susan Holley

Clinical Director

Onsite Women's Health

‍

Whiterabbit has been a fantastic partner in helping us modernize our breast cancer risk assessment program.  From the start, they really listened to us, understood what we needed and provided a sleek, agile program to give answers to our patients.  Whiterabbit has been a joy to work with, and are unfailingly nimble, insightful and quick – we greatly appreciate their depth of skill, from programming to design to breast cancer statistics.  With WRDensity, we are better able to manage our most at-risk patients.

‍

Dr. Susan Holley

Clinical Director

Onsite Women's Health

‍

Unique Features

WRDensity’s powerful deep learning model delivers highly accurate breast density classification.³

‍

Our batching and sorting feature delivers up to a 20% increase in productivity for users of the product.⁴

WRDensity is presented within the radiologist’s existing workstation making relevant tissue density information available in context.

Find out how our products can help your business increase compliance, increase revenue and improve outcomes.

Request A Demo
News & Research
News
RadNet and Whiterabbit.ai Form a Comprehensive Partnership to Address Mammography Compliance and Improved Diagnostics for Breast Cancer
Read More
View More
News & Research
No items found.
View More
News & Research
Research
A Multi-site Study of a Breast Density Deep Learning Model for FFDM and DBT
Read More
Research
A Hypersensitive Breast Cancer Detector - Oral presentation at the SPIE Medical Imaging Conference 2020
Read More
View More
Footnotes

1 Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000;92(13):1081–1087
2 Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K, for the Breast Cancer Surveillance Consortium. Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer. JAMA Oncol. 2017;3(9):1228–1236.
3 Whiterabbit data on file.
4 Whiterabbit data on file.

Products

ACT
ACT ROI
WRDensity
WRRisk
Request a Demo

Company

AboutOur TeamCareersContact

Privacy Policy

End User Agreement

Copyright © , Whiterabbit.ai